419 POSTER A phase I safety and pharmacokinetic (PK) study of 3 and 6 hours (h) intravenously administered belinostat (PXD101) plus carboplatin (C) and paclitaxel (P) in patients (pts) with advanced solid tumours
M. Sorensen, J. Tjørnelund, P.B. JensenVolume:
6
Year:
2008
Language:
english
DOI:
10.1016/s1359-6349(08)72353-x
File:
PDF, 63 KB
english, 2008